Rabbani Syed | Pharmaco-Oncology | Innovative Research Award

Innovative Research Award

Rabbani Syed
King Saud University, Saudi Arabia

Rabbani Syed
Affiliation King Saud University
Country Saudi Arabia
Scopus ID 35751491100
Documents 95
Citations 1,703
h-index 21
Subject Area Pharmaco-Oncology
Event International Research Awards on Oncology and Cancer Research
ORCID 0000-0003-4695-0645

The Innovative Research Award recognizes research activity that contributes to the development of new knowledge, methodologies, or applications within a defined academic discipline. This profile presents the available research information associated with Rabbani Syed of King Saud University, Saudi Arabia, in the context of the International Research Awards on Oncology and Cancer Research.

Abstract

This academic recognition profile documents the supplied research information of Rabbani Syed, affiliated with King Saud University in Saudi Arabia. The researcher is associated with the subject area of Pharmaco-Oncology and has been proposed in connection with the Innovative Research Award. The available bibliometric information includes 95 documents, 1,703 citations, and an h-index of 21. These indicators offer a measurable description of scholarly activity but do not, by themselves, establish the originality or practical effectiveness of individual studies. Further evaluation requires examination of publications, research methods, and documented contributions.

Keywords

Keywords: Innovative Research Award, Rabbani Syed, King Saud University, Saudi Arabia, Pharmaco-Oncology, cancer research, oncology, pharmaceutical research, bibliometrics, scholarly publications, therapeutic research, research recognition.

Introduction

Pharmaco-Oncology encompasses research involving medicines, drug mechanisms, therapeutic development, and pharmacological strategies relevant to cancer care. Innovation in this field may involve the discovery of candidate compounds, investigation of drug responses, improvements in drug-delivery systems, or the evaluation of treatment-related biological mechanisms. Research recognition in this area requires consideration of the scientific question, methodological rigor, reproducibility, and potential relevance to oncology. [2]

Research Profile

Rabbani Syed is identified in the supplied information as a researcher affiliated with King Saud University, Saudi Arabia. The provided Scopus author identifier is 35751491100, while the ORCID identifier is 0000-0003-4695-0645. The supplied profile statistics indicate 95 documents, 1,703 citations, and an h-index of 21. These figures should be interpreted with reference to the date of retrieval and the specific author record. [1]

Research Contributions

The supplied subject classification places the researcher within Pharmaco-Oncology. However, detailed information about specific research projects, experimental findings, patented technologies, clinical investigations, or methodological innovations has not been provided. Consequently, individual contributions cannot be independently described in detail. A comprehensive assessment would examine the originality of the research questions, the quality of the evidence, and the relevance of reported findings to oncology and pharmaceutical science. [3]

Publications

The supplied information reports a total of 95 documents associated with the researcher’s academic record. A complete publication list, including article titles, journals, publication dates, co-authors, and digital object identifiers, was not supplied for this profile. The Scopus author record may provide a starting point for examining indexed publications and related citation information. Publication-level verification is necessary before attributing specific scientific findings or research achievements.

Research Impact

The reported citation count of 1,703 and h-index of 21 provide quantitative indicators of the researcher’s documented scholarly visibility. Citation measures can assist in describing patterns of academic attention, but they may be influenced by publication age, disciplinary practices, collaboration patterns, and database coverage. They should therefore be considered alongside qualitative evidence, including research reproducibility, scientific influence, and documented applications. [4]

Award Suitability

The Innovative Research Award is associated with research that demonstrates originality and meaningful advancement within a relevant field. The supplied affiliation, subject area, publication count, citation count, and h-index provide contextual information for an academic review. A formal award assessment should additionally consider the nominee’s documented innovations, supporting publications, research significance, and compliance with the event’s eligibility criteria. The available information alone does not establish the outcome of an award evaluation.

Conclusion

Rabbani Syed is identified in the supplied data as a King Saud University researcher working in the subject area of Pharmaco-Oncology. The reported record includes 95 documents, 1,703 citations, and an h-index of 21. These metrics summarize selected aspects of scholarly activity. Further information about research innovations, individual publications, and documented scientific outcomes would be required to develop a more comprehensive academic assessment in relation to the Innovative Research Award.

References

  1. Elsevier. (n.d.). Scopus author details: Rabbani Syed, Author ID 35751491100. Scopus.https://www.scopus.com/authid/detail.uri?authorId=35751491100
  2. National Cancer Institute. (n.d.). Drug therapy and cancer treatment research. National Cancer Institute.https://www.cancer.gov/about-cancer/treatment/types
  3. Hanahan, D. (2022). Hallmarks of cancer: New dimensions. Cancer Discovery, 12(1), 31–46.https://doi.org/10.1158/2159-8290.CD-21-1059
  4. Hirsch, J. E. (2005). An index to quantify an individual’s scientific research output. Proceedings of the National Academy of Sciences, 102(46), 16569–16572.https://doi.org/10.1073/pnas.0507655102
  5. ORCID. (n.d.). ORCID: Connecting research and researchers. ORCID.https://orcid.org/0000-0003-4695-0645

Yingxue Jin | Pharmaco-Oncology | Excellence in Oncology Research Award

Prof. Dr. Yingxue Jin | Pharmaco-Oncology | Excellence in Oncology Research Award

Harbin Normal University | China

AUTHOR PROFILE

Scopus

🧑‍🏫 YINGXUE JIN – PROFESSIONAL PROFILE

🎓 EARLY ACADEMIC PURSUITS

Yingxue Jin embarked on his academic journey with a strong foundation in science, eventually earning a Doctor of Science degree from Pusan National University in Korea in 2003. His academic background laid the groundwork for his expertise in pharmaceutical engineering and drug design. During his doctoral studies, he specialized in small molecule cyclic peptide drugs and nanodrug delivery systems, establishing a solid base for his future research contributions.

💼 PROFESSIONAL ENDEAVORS

Yingxue Jin has accumulated over three decades of experience in academia and research, holding key positions in prestigious institutions and companies:

  • Professor at Jiamusi University (1990 – 1999): Contributed to teaching and research in pharmaceutical sciences.

  • Senior Researcher at Korea Ilshin Chemical Company (2003 – 2004): Engaged in advanced chemical research, expanding his expertise in molecular synthesis.

  • Postdoctoral Researcher at Taiwan University, China (2005 – 2006): Conducted postdoctoral studies, refining his knowledge in pharmaceutical engineering and drug delivery mechanisms.

  • Professor at Harbin Normal University, China (2006 – Present):

    • Serving as Head of the Department of Pharmaceutical Engineering.

    • Director of Heilongjiang Chemical Society of China, promoting chemical science advancements.

    • Awarded the honorary title of “Famous Teacher” at Harbin Normal University, recognizing his excellence in education and mentorship.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON PHARMACO-ONCOLOGY

Yingxue Jin’s primary research interests revolve around:

  • Design and Synthesis of Small Molecule Cyclic Peptide Drugs: Developing novel peptide-based therapeutic agents for various diseases, including cancer.

  • Anti-Tumor Nanodrug Delivery Systems: Innovating targeted drug delivery methods to enhance the efficacy and precision of cancer treatments.

  • Project Leadership:

    • Presided over two projects funded by the Natural Science Foundation of China (NSFC).

    • Led the implementation of one key project and two general projects under the Natural Science Foundation of Heilongjiang Province, China.

    • Supervised three natural science projects for the Heilongjiang Provincial Education Department, China.

🏅 IMPACT AND INFLUENCE

Yingxue Jin’s impactful contributions have been widely recognized through multiple awards and honors:

  • Natural Science and Technology Award of Heilongjiang Province: Acknowledging his significant scientific achievements.

  • Science and Technology Award of Heilongjiang Provincial Education Department: Recognizing his contributions to technological advancements in education.

  • Teaching Quality Award at Harbin Normal University (Multiple Occasions): Honoring his dedication to educational excellence and mentorship.

📚 ACADEMIC CITATIONS

Throughout his career, Yingxue Jin’s research has been widely cited in scientific publications, reflecting the influence and relevance of his work in the fields of pharmaceutical sciences, chemical engineering, and nanomedicine. His contributions have been referenced in numerous peer-reviewed journals, further establishing his reputation as a leading researcher in his field.

🌍 LEGACY AND FUTURE CONTRIBUTIONS

Yingxue Jin’s legacy is marked by his dedication to scientific innovation, educational mentorship, and pharmaceutical advancements. Moving forward, he aims to:

  • Expand his research in nanodrug delivery systems, focusing on precision medicine for oncology applications.

  • Foster collaborations with international research institutions to drive cross-disciplinary advancements.

  • Continue mentoring the next generation of scientists, contributing to the development of future leaders in pharmaceutical sciences.

🛡️ KEY ACHIEVEMENTS AND RECOGNITION

  • Honorary Title: Famous Teacher of Harbin Normal University.

  • Leadership Roles: Head of the Department of Pharmaceutical Engineering and Director of Heilongjiang Chemical Society of China.

  • Award-Winning Scientist: Recipient of multiple science and technology awards.

  • Renowned Educator: Consistently recognized for outstanding teaching quality.

🚀 CONCLUSION

Yingxue Jin’s extensive experience, innovative research, and dedication to scientific excellence and education have positioned him as a distinguished figure in the field of pharmaceutical sciences. His continued contributions to nanodrug delivery systems and cyclic peptide drug design are paving the way for groundbreaking advancements in cancer treatment and precision medicine.

 

📊🔬NOTABLE PUBLICATION:
  • 1️⃣ Exploring the Potential of Cyclic Peptidyl Antitumor Agents Derived from Natural Macrocyclic Peptide Phakellistatin 13

    Authors: Tong T. Li, Shitian S. Jiang, Tingting T. Li, Yingxue Y. Jin, Zhiqiang Z. Wang
    Journal: Journal of Medicinal Chemistry
    Year: 2024


    2️⃣ Enhanced Catalytic Activity of Fe3O4-Carbon Dots Complex in the Fenton Reaction for Enhanced Immunotherapeutic and Oxygenation Effects

    Authors: Guanghao G. Li, Yujun Y. Bao, Hui H. Zhang, Zhiqiang Z. Wang, Yingxue Y. Jin
    Journal: Journal of Colloid and Interface Science
    Year: 2024


    3️⃣ A Novel Nanomedicine Integrating Ferroptosis and Photothermal Therapy, Well-Suitable for PD-L1-Mediated Immune Checkpoint Blockade

    Authors: Yujun Y. Bao, Guanghao G. Li, Siqi S. Li, Changhong C. Guo, Yingxue Y. Jin
    Journal: Materials Today Bio
    Year: 2024


    4️⃣ Targeted Delivery of Rhein via Hyaluronic Acid Modified Liposomes for Suppression of Growth and Metastasis of Breast Cancer

    Authors: Jingchun J. Wang, Dijing D. Fan, Defu D. Cai, Yingxue Y. Jin
    Journal: International Journal of Biological Macromolecules
    Year: 2024


    5️⃣ DFT-Aided Stereo-Structural and Electronic Structure Studies of Poly-Hydroxyl Substituted Chlorophyllous Molecules

    Authors: Xiong X. Zhang, Tingting T. Li, Qi Q. Wang, Wen W. Fang, Zhiqiang Z. Wang
    Journal: Computational and Theoretical Chemistry
    Year: 2024